Progressive Fibrosing Interstitial Lung Disease Market to Register Positive Growth at a CAGR of 7.6% by 2032 | DelveInsight

The progressive fibrosing interstitial lung disease market is anticipated to increase due to factors such as increased awareness of PF-ILD along with the expected launch of emerging therapies during the forecast period (2022–2032) in the 7MM markets.

LAS VEGAS, Sept. 6, 2022 /PRNewswire/ -- DelveInsight's Progressive Fibrosing Interstitial Lung Disease Market Insights report includes a comprehensive understanding of current treatment practices, progressive fibrosing interstitial lung disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Progressive Fibrosing Interstitial Lung Disease Market Report

• As per DelveInsight analysis, the progressive fibrosing interstitial lung disease market size in the 7MM was approximately USD 4,205 million in 2021.
• As per the estimates, the total progressive fibrosing interstitial lung disease diagnosed prevalent cases in the 7MM were approximately 322K in 2021. 
• Leading progressive fibrosing interstitial lung disease companies such as Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb along with IPF-specific PF-ILD like Hoffmann-La Roche Ltd, FibroGen, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others are developing novel progressive fibrosing interstitial lung disease drugs that can be available in the progressive fibrosing interstitial lung disease market in the upcoming years.
• The progressive fibrosing interstitial lung disease therapies in the pipeline include BI 1015550, BMS-986278 along with IPF-specific PF-ILD drugs like Pamrevlumab, PRM-151 (RG6354), PLN-74809, Tyvaso (inhaled treprostinil), C21 (VP01), and others.
• The increase in progressive fibrosing interstitial lung disease market size is a direct consequence of the increasing prevalent population of PF-ILD along with the upcoming therapies in the 7MM.

Discover which therapies are expected to grab major progressive fibrosing interstitial lung disease market share @Progressive Fibrosing Interstitial Lung Disease Market Report

Progressive Fibrosing Interstitial Lung Disease Overview

Progressive fibrosing interstitial lung disease (PF-ILD) are a group of interstitial lung diseases (ILD) that share a clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.

Idiopathic interstitial pneumonia such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD, SSc-related ILD, and sarcoidosis are all examples of PF-ILDs.

The differential diagnosis of ILDs requires a multidisciplinary approach, usually involving pulmonologists, radiologists, and pathologists. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging, and, if required, lung biopsy.

Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmentation

As per DelveInsight, there were approximately 322K progressive fibrosing interstitial lung disease diagnosed prevalent cases in the 7MM in 2021.

Among the 7MM countries, the US had the highest prevalence of PF-ILD in 2021.

The progressive fibrosing interstitial lung disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalent Cases of ILD 
• Total Diagnosed Prevalent Cases of ILD 
• Type-specific Diagnosed Prevalent Cases of ILD 
• Total Diagnosed Prevalent Cases of PF-ILD 

Download the report to understand which factors are driving progressive fibrosing interstitial-lung disease epidemiology trends @Progressive Fibrosing Interstitial Lung Disease Epidemiological Insights

Progressive Fibrosing Interstitial Lung Disease Treatment Market 

PF-ILD treatments that act on the fibrotic pathway are required to slow the progression of fibrosis. This justifies further research into pirfenidone and nintedanib, both of which have been shown to slow disease progression in IPF patients. Other than IPF, there are few treatment options for advanced fibrotic ILD. Pirfenidone use in PPF patients is associated with a statistically significant reduction in disease progression and protection of lung function.

Corticosteroids, except nintedanib and pirfenidone, are commonly used as first-line therapies for ILDs other than IPF, but there is little evidence to support their efficacy in ILD treatment. Except for acute exacerbations, international guidelines for IPF treatment strongly recommend corticosteroid monotherapy.

Other therapies used as second-line treatment for SSc-ILD included cyclophosphamide, azathioprine, and mycophenolate mofetil, which were used by 18%, 16%, and 13% of physicians surveyed, respectively.

To know more about progressive fibrosing interstitial lung disease treatment, visit @New Treatment for Progressive Fibrosing Interstitial Lung Disease

Progressive Fibrosing Interstitial Lung Disease Pipeline Therapies and Key Companies

• BI 1015550: Boehringer Ingelheim
• BMS-986278: Bristol-Myers Squibb
• Pamrevlumab: FibroGen
• PRM-151 (RG6354): Hoffmann-La Roche Ltd
• PLN-74809: Pliant Therapeutics, Inc.
• Tyvaso (inhaled treprostinil): United Therapeutics
• C21 (VP01): Vicore Pharma AB

Learn more about the progressive fibrosing interstitial lung diseases therapies in clinical trials @Drugs for PF-ILD Treatment 

Progressive Fibrosing Interstitial Lung Disease Market Dynamics

The growing prevalence of PF-ILD worldwide, due to delayed accurate diagnosis and the lack of curative treatment options for ILDs, is likely to increase the demand for treatment options in the progressive fibrosing interstitial lung disease market. As a result, the revenue-progressive fibrosing interstitial lung diseases market may increase in the coming years.

Moreover, the current ILD biomarker research demonstrates that the identified biomarkers' activities are useful for diagnosing, prognosis, and treating ILD patients with progressive phenotypes. This trend is expected to strengthen the future progressive fibrosing interstitial lung disease market.

Furthermore, the lack of curative therapies with fewer side effects may open up progressive fibrosing interstitial lung disease market space for emerging therapies, as currently approved therapies cannot reverse the disease and have associated side effects. Additionally, due to limited development in the mechanism of action of upcoming therapies, investors have a great opportunity to develop novel emerging therapies in the progressive fibrosing interstitial lung disease market.

However, the availability of supportive therapies with higher tolerability and cost-effectiveness may impede the market acceptance of progressive fibrosing interstitial lung disease of approved drugs. Many emerging products' clinical development has been hampered by significant challenges, such as a lack of sensitive clinical outcomes, suitable biomarkers, and difficulty in recruiting subjects, resulting in project delays or cancellations, thus hindering the growth of the progressive fibrosing interstitial lung disease market. 

Moreover, clinical development failure weakens the emerging pipeline. Many drugs have been withdrawn due to clinical challenges in later stages, implying that current emerging drugs may fail. They will disrupt progressive fibrosing interstitial lung disease market growth if it happens.  Furthermore, as the disease etiology is complex and most of the disease pathology is unknown, drug development for PF-ILD is jeopardized.

Scope of the Progressive Fibrosing Interstitial Lung Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Progressive Fibrosing Interstitial Lung Disease Companies: Boehringer Ingelheim Pharmaceuticals, Inc., Hoffmann-La Roche Ltd, Bristol-Myers Squibb, FibroGen, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others
• Key Progressive Fibrosing Interstitial Lung Disease Therapies: BI 1015550, BMS-986278, Pamrevlumab, PRM-151 (RG6354), PLN-74809, Tyvaso (inhaled treprostinil), C21 (VP01), and others
• Therapeutic Assessment: Progressive Fibrosing Interstitial Lung Disease current marketed and emerging therapies
• Progressive Fibrosing Interstitial Lung Diseases Market Dynamics:  Progressive Fibrosing Interstitial Lung Disease market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Progressive Fibrosing Interstitial Lung Disease Market Access and Reimbursement

Discover more about drugs for PF-ILD in development @PF-ILD Clinical Trials

Table of Contents 

Get in touch with our Business executive @Healthcare Due Diligence Services 

Related Reports

Interstitial Lung Disease Epidemiology Forecast

Interstitial Lung Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of interstitial lung disease, historical and forecasted epidemiology, and interstitial lung disease epidemiology trends.

Interstitial Lung Disease Market

Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key interstitial lung disease companies, including AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, among others.

Systemic Sclerosis Associated Interstitial Lung Disease Pipeline

Systemic Sclerosis Associated Interstitial Lung Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key systemic sclerosis-associated interstitial lung disease companies, including Beijing Continent Pharmaceutical Co, Ltd., Shanghai Genomics, Inc., GNI-EPS Pharmaceuticals, Inc., among others.

Systemic Sclerosis Associated Interstitial Lung Disease Market

Systemic Sclerosis Associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key systemic sclerosis-associated interstitial lung disease companies, including Beijing Continent Pharmaceutical Co, Ltd., Shanghai Genomics, Inc., GNI-EPS Pharmaceuticals, Inc., among others.

Progressive Fibrosing Interstitial Lung Disease Pipeline

Progressive Fibrosing Interstitial Lung Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key progressive fibrosing interstitial lung disease companies, including Sunshine Lake Pharma Co., Ltd., Boehringer Ingelheim, Hoffmann-La Roche, among others.

Other Trending Reports

Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg